Bio-Rad executives said this week that first-quarter sales of the firm's digital PCR platform and related products increased year over year, helping to drive approximately 1 percent year-over-year and 2.5 percent sequential growth in the company's Life Science segment.

The uptick in Life Science sales buoyed Bio-Rad's overall revenues, which crept up 3 percent year over year but fell short of consensus analyst estimates on the top and bottom lines due to what the company called "softness" in research markets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.